Discovery of a First-in-Class Receptor Interacting Protein 1 (RIP1) Kinase Specific Clinical Candidate (GSK2982772) for the Treatment of Inflammatory Diseases

Post time 2022-12-21 12:39:51

journal：Journal of Medicinal Chemistry

Authors：Philip A. Harris; Scott B. Berger; Jae U. Jeong; Rakesh Nagilla; Deepak Bandyopadhyay; Nino Campobasso; Carol A. Capriotti; Julie A. Cox; Lauren Dare; Xiaoyang Dong; Patrick M. Eidam; Joshua N. Finger; Sandra J. Hoffman; James Kang; Viera Kasparcova; Bryan W. King; Ruth Lehr; Yunfeng Lan; Lara K. Leister; John D. Lich; Thomas T. MacDonald; Nathan A. Miller; Michael T. Ouellette; Christina S. Pao; Attiq Rahman; Michael A. Reilly; Alan R. Rendina; Elizabeth J. Rivera; Michelle C. Schaeffer; Clark A. Sehon; Robert R. Singhaus; Helen H. Sun; Barbara A. Swift; Rachel D. Totoritis; Anna Vossenkamper; Paris Ward; David D. Wisnoski; Daohua Zhang; Robert W. Marquis; Peter J. Gough; John Bertin

Published date：2017-2-23

DOI：10.1021/acs.jmedchem.6b01751

Article link：http://dx.doi.org/10.1021/acs.jmedchem.6b01751

Article Source：American Chemical Society (ACS)。

Remark：

Post time 2022-12-21 12:39:52

: This post has been completed
Completed attachments will be deleted within 24 hours.

Post time 2022-12-21 12:43:13

: This post has been completed
Completed attachments will be deleted within 24 hours.

Post time 2022-12-21 12:44:41

: This post has been completed
Completed attachments will be deleted within 24 hours.

[ACS] Discovery of a First-in-Class Receptor Interacting Protein 1 (RIP1) Kinase Specific Clinical Candidate (GSK2982772) for the Treatment of Inflammatory Diseases

Best Answer

Same Category

Latest Reply

Announcement

Enthusiastic users today